Navigation Links
Arthritis sufferers fund arthritis research
Date:2/19/2008

The Queensland and Northern New South Wales Lions Medical Research Foundation, long time supporters of the Brisbane research community, have confirmed funding of $1.2 million for scientists at UQ's Diamantina Institute.

Dr Gethin Thomas will be the inaugural recipient of the $300,000 three-year fellowship, which will fund his research investigating the causes of ankylosing spondylitis (AS).

This is a form of arthritis affecting the spine resulting in joint fusion and immobility, and osteoporosis, a disease characterised by bone loss and frequent fracture.

This funding will enable us to focus on our longer-term goals of identifying the underlying causes of these diseases and developing new drugs and therapies, Dr Thomas said.

There is an urgent need for new therapies in these diseases that will enable reversal of disease damage.

The current therapies can only prevent progression of AS and osteoporosis but cannot repair already damaged bones and joints.

Unfortunately sufferers are frequently not diagnosed until fracture or loss of mobility by which time degeneration of the bones or joints is already significant.

Irene Dunning, Lions Foundation Chairman, said she was pleased Dr Thomas had received the first installment of the new Fellowship.

I think it's good to be supporting something which will potentially help a lot of Lions members," she said.

Osteoporosis and arthritis are diseases that affect many Lions members and their families and friends.

Lions members will further contribute to the research by volunteering as participants in the studies providing a valuable resource for our research efforts and creating a mutually beneficial synergy.


'/>"/>

Contact: Penny Robinson
penny.robinson@uq.edu.au
61-733-659-723
Research Australia
Source:Eurekalert

Page: 1

Related medicine news :

1. Study Suggests Glucosamine Wont Ease Hip Arthritis
2. Gene Linked to Inflammatory Arthritis Also Raises Heart Risks
3. Rheumatoid arthritis sends many into early retirement
4. Depression not discussed during rheumatoid arthritis doctor visits
5. The HLA-DRB1 gene and premature death in rheumatoid arthritis
6. Newer Rheumatoid Arthritis Drugs Lower Production of B Cells
7. Popular arthritis drug may disrupt heart rhythm, UB research finds
8. Exercise Program Eases Arthritis
9. A new view of drugs used to treat rheumatoid arthritis
10. Genes Linked to Height Also Tied to Osteoarthritis Risk
11. Modified-Release Prednisone May Ease Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... KING OF PRUSSIA, PA and LONDON, UK (PRWEB) , ... May ... ... continues to earn accolades for his success in changing the way the pharmaceutical industry ... Power 100 list of the world’s most influential people in pharma, and he was ...
(Date:5/6/2016)... Chandler, AZ (PRWEB) , ... May 06, 2016 ... ... No Greater Odds, are scheduled to provide a unique keynote address at the ... documentary follows the inspirational stories of five community college students. Their stories—of complicated ...
(Date:5/6/2016)... ... ... A wide variety of national pet product manufacturers, companies and brands will gather for one ... 18 from noon to 8 p.m. at New York City’s Roger Smith Hotel. The event ... garden, outdoor and safety pet products in today’s marketplace. , Petrend Event showcases ...
(Date:5/6/2016)... Jupiter, FL (PRWEB) , ... May 06, 2016 ... ... it will feature AsedaSciences® in an upcoming episode, airing third quarter 2016, via ... with the vision of becoming a leader in optimized drug discovery through innovative ...
(Date:5/6/2016)... Pass, OR (PRWEB) , ... May 06, 2016 , ... ... eyes. In other seasons, when the weather is too cold, dry or hot, water ... the eyes can actually absorb moisture from the surrounding air. There’s only one problem, ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... ZIONA, Israel , May 4, ... TASE: BVXV) announced today that BiondVax,s CEO, Dr. Ron ... conference in New York City . ... at 10:30am at Pioneers 2016, a conference presented by ... York Palace Hotel. The BiondVax presentation that Dr. ...
(Date:5/4/2016)... May 4, 2016 Yissum ... announced today that it had signed an exclusive ... , developer of novel protein degradation and immunomodulatory drugs ... commercialization of drug candidates representing first-in-class therapy for hematologic ... not disclosed. The novel technology was developed ...
(Date:5/4/2016)... , May 4, 2016 ... completion of an alternative public offering (APO). This was ... operating company, Valeritas, Inc. and a private placement of ... at $5.00 per share. Under the terms ... 3, 2016, Valeritas Holdings, Inc. will trade on the ...
Breaking Medicine Technology: